Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
about
Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer CellsEvolving Therapies and FAK Inhibitors for the Treatment of CancerPTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors.Reactive oxygen species is essential for cycloheximide to sensitize lexatumumab-induced apoptosis in hepatocellular carcinoma cellsSystemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesotheliomaThe scavenging of superoxide radicals promotes apoptosis induced by a novel cell-permeable fusion protein, sTRAIL:FeSOD, in tumor necrosis factor-related apoptosis-inducing ligand-resistant leukemia cells.Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatinAdvances in phage display technology for drug discovery.Probe-Based Confocal Laser Endomicroscopy for Imaging TRAIL-Expressing Mesenchymal Stem Cells to Monitor Colon Xenograft Tumors In Vivo.Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.Evolution of phage display technology: from discovery to application.Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy.Stem cells as vectors for antitumour therapy.Novel targeted therapies and vaccination strategies for mesothelioma.Caspase control: protagonists of cancer cell apoptosis.Antitumor effects of TRAIL-expressing mesenchymal stromal cells in a mouse xenograft model of human mesothelioma.Development of a human three-dimensional organotypic skin-melanoma spheroid model for in vitro drug testing.The role of Bcl-xL in synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia on human colon cancer.Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer.Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.Down-regulation of DcR2 sensitizes androgen-dependent prostate cancer LNCaP cells to TRAIL-induced apoptosis.
P2860
Q28391040-9B60375E-E02E-4271-896D-37B5C9DA7171Q28972291-04CFFA19-BFFF-4BD5-94F9-01F0F2C13187Q31122542-440DDC78-4BAC-4DC9-8EE9-263B46D88DA0Q33502208-E16B0791-1A38-400A-9482-CAC1035EF033Q33618126-13C86FF6-B97F-4EB9-9D1B-AD8754F9A993Q33828562-51722329-9321-4BE0-B367-21AFB498453EQ33834736-59E40DDE-19EB-478C-9289-3E807D5A2DD0Q33850307-62138301-4AB9-4588-9351-B9CF0E92F5DEQ34501203-6DB23445-00C1-4FBA-A8B6-A8E132519409Q35614190-2F03B5D3-B0D3-4B2D-8196-B4482423CB9DQ36129857-22640E56-21C5-48B2-8799-83D6E95D3695Q36159154-E9F9A0A6-52DA-4CCB-B42E-3840EDAD8693Q36183954-B3F4DDEF-66F5-47A9-A92E-DA4AFFCAED51Q37621564-1DA2F937-E9FD-4465-9684-CAF174A1A01CQ37730300-4F840A7E-A5D5-426F-8D91-6C404FBD4B33Q37855667-402945C7-94C2-4C50-A385-B60161B42694Q38052382-8F39BC7F-6F3F-42A0-97AC-2C2750CF84C4Q38927008-9096FFCB-1003-43CE-8D3A-C292BA260D39Q39127177-FCBCFFF1-73A4-469E-BF6B-02446A45BBE2Q39262774-A48F4E73-7DF6-4954-ADE0-989842AC5C3CQ39790634-FF3CF68D-D868-442E-B449-A89B76AB88C4Q41279899-F77C2211-ECD3-43E6-8D77-D074B99EBE85Q41532348-E221E74B-C92C-484C-B3B0-5D2963AD4ACC
P2860
Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Human agonistic TRAIL receptor ...... ynergistically with cisplatin.
@ast
Human agonistic TRAIL receptor ...... ynergistically with cisplatin.
@en
type
label
Human agonistic TRAIL receptor ...... ynergistically with cisplatin.
@ast
Human agonistic TRAIL receptor ...... ynergistically with cisplatin.
@en
prefLabel
Human agonistic TRAIL receptor ...... ynergistically with cisplatin.
@ast
Human agonistic TRAIL receptor ...... ynergistically with cisplatin.
@en
P2093
P2860
P356
P1433
P1476
Human agonistic TRAIL receptor ...... synergistically with cisplatin
@en
P2093
Larisa L Belyanskaya
Rolf A Stahel
Sally Hopkins-Donaldson
Stefanie Kurtz
Thomas M Marti
P2860
P2888
P356
10.1186/1476-4598-6-66
P577
2007-10-22T00:00:00Z
P5875
P6179
1000865155